How Nordic Nanovector Stepped Back From The Abyss With APIM Merger
Picked Fellow Norwegian Firm After Multiple Talks
Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.
You may also be interested in...
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
The company still sees a potential future for Betalutin and hopes to partner the asset as it looks to focus on the rest of its pipeline.
Europe does not have a pricing environment that rewards innovation which improves outcomes for patients, according to Vas Narasimhan, although Germany seems to be the best of a bad bunch.